Abstract: Objective The purpose of this study was to investigate the short-term clinical efficacy of transcatheter arterial chemoembolization (TACE) and three-dimensional conformal radiotherapy(3D-CRT) in the treatment of patients with advanced primary liver cancer (PLC). Methods 89 patients with advanced PLC were admitted to our hospital between January 2015 and September 2020, and all the patients were treated with TACE and 3D-CRT combination therapy. The short-term clinical efficacy were evaluated, and the multivariate Logistic regression analysis was conducted to explore the influencing factors on the short-term clinical efficacy. Results At the end of three-month treatment, the effective rate was 71.9% in our series, including complete remission (CR) 17 cases, partial remission (PR) in 43 cases, stable disease (SD) in 21 cases and progression of disease (PD) in 8 cases; the univariate Logistic regression analysis showed that the percentage of BCLC stage B, Child-Pugh class A, tumor diameter less than 5 cm, serum AFP less than 400.0 μg/L, the neutrophils to lymphocytes ratio (NLR) and the prognostic nutritional index (PNI) in patients with CR/PR were 71.7%, 76.7%,46.7%,81.7%,53.3% and 75.0%, all significantly different compared to 34.5%, 48.3%, 20.7%, 34.5%, 31.0% and 31.0%(P＜0.05); the multivariate Logistic regression analysis showed that the Child-Pugh class B (OR=1.749), serum AFP level >400.0 μg/L(OR=1.988), and PNI<45(OR=1.627) were the independent risk factors affecting the short-term clinical efficacy (P＜0.05). Conclusion The short-term clinical efficacy of TACE and 3D-CRT combination in dealing with patients with advanced PLC is good, and the clinicians should choose the appropriate and eligible patients to receive the protocol for improved efficacy.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Linear accelerator three-dimensional conformal radiotherapy, Therapy